A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory/resistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.

Trial Details

NCT ID
NCT07545122
Phase
PHASE1
Sponsor
Context Therapeutics Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • CT-202
Locations (sample)
  • Wahroonga, New South Wales, Australia|-33.71816,151.11561
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Gold Coast, Queensland, Australia|-28.00029,153.43088
  • Newcastle, Queensland, Australia
  • Heidelberg, Victoria, Australia|-37.75,145.06667

Key Eligibility Criteria

  • Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies
  • Participants with measurable disease per RECIST 1.1
  • ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks
  • Participants have adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →